The use of enrichment to reduce statistically indeterminate or negative trials in critical care

Anaesthesia

Volumn 72, Issue 5, 2017, Pages 560-565

  Shankar Hari, M ^a,b   Rubenfeld, G D ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

ARDS; critical care; enrichment; heterogeneity; sepsis

Indexed keywords

COLONY STIMULATING FACTOR 1; CORTICOSTEROID; ENDOTOXIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVERSE OUTCOME; ARTIFICIAL VENTILATION; ATTRIBUTABLE RISK; CLINICAL PRACTICE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; EDITORIAL; ENDOTHELIUM INJURY; ENVIRONMENTAL FACTOR; EQUIPOISE; HEART OUTPUT; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MORTALITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; TREATMENT RESPONSE; METHODOLOGY; RANDOMIZATION;

CRITICAL CARE; DISEASE SUSCEPTIBILITY; HUMANS; NEGATIVE RESULTS; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85015673676     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/anae.13870     Document Type: Editorial

References (41)

1. Rubin DB. Causal inference using potential outcomes. Journal of the American Statistical Association 2005; 100: 322–31.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal 2008; 336: 924–6.
3. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Group C Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. Journal of the American Medical Association 2012; 308: 2594–604.
4. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. Journal of the American Medical Association 2012; 307: 2526–33.
5. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Journal of the American Medical Association 2016; 315: 801–10.
6. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock. Journal of the American Medical Association 2016; 315: 775–87.
7. Sackett DL. Why randomized controlled trials fail but needn't. Canadian Medical Association Journal 2001; 165: 1226–37.
8. Feudtner C, Schreiner M, Lantos JD. Risks (and benefits) in comparative effectiveness research trials. New England Journal of Medicine 2013; 369: 892–4.
9. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infectious Diseases 2015; 15: 581–614.
10. Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet 2016; 388: 2416–30.
11. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Journal of the American Medical Association 2016; 315: 788–800.
12. Pearson H. Epidemiology: study of a lifetime. Nature 2011; 471: 20–4.
13. Smith GD. Epidemiology, epigenetics and the ‘Gloomy Prospect’: embracing randomness in population health research and practice. International Journal of Epidemiology 2011; 40: 537–62.
14. Shankar-Hari M, Harrison DA, Rowan KM. Differences in impact of definitional elements on mortality precludes international comparisons of sepsis epidemiology-a cohort study illustrating the need for standardized reporting. Critical Care Medicine 2016; 44: 2223–30.
15. Shaver CM, Bastarache JA. Clinical and biological heterogeneity in acute respiratory distress syndrome: direct versus indirect lung injury. Clinics in Chest Medicine 2014; 35: 639–53.
16. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. Journal of Experimental Medicine 2011; 208: 2581–90.
17. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370: 676–84.
18. Goligher EC, Kavanagh BP, Rubenfeld GD, Ferguson ND. Pro: physiologic responsiveness should guide entry into randomized controlled trials. American Journal of Respiratory and Critical Care Medicine 2015; 192: 1416–9.
19. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials 2014; 15: 218.
20. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. American Journal of Respiratory and Critical Care Medicine 2009; 180: 640–8.
21. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. Journal of the American Medical Association 2008; 300: 413–22.
22. Cowley NJ, Owen A, Millar J, et al. Antiviral prophylaxis inhibits cytomegalovirus reactivation in critical illness. Critical Care 2015; 19: P115.
23. Goligher EC, Kavanagh BP, Rubenfeld GD, et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. American Journal of Respiratory and Critical Care Medicine 2014; 190: 70–6.
24. Rindskopf D, Rindskopf W. The value of latent class analysis in medical diagnosis. Statistics in Medicine 1986; 5: 21–7.
25. Dalton L, Ballarin V, Brun M. Clustering algorithms: on learning, validation, performance, and applications to genomics. Current Genomics 2009; 10: 430–45.
26. Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine 2016; 4: 259–71.
27. Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome subphenotypes respond differently to randomized fluid management strategy. American Journal of Respiratory and Critical Care Medicine 2017; 195: 331–8.
28. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respiratory Medicine 2014; 2: 611–20.
29. Shankar-Hari M, McAuley DF. Acute respiratory distress syndrome phenotypes and identifying treatable traits. The dawn of personalized medicine for ARDS. American Journal of Respiratory and Critical Care Medicine 2017; 195: 280–1.
30. Wong HR, Atkinson SJ, Cvijanovich NZ, et al. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Critical Care Medicine 2016; 44: e1000–3.
31. Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. American Journal of Respiratory and Critical Care Medicine 2015; 191: 309–15.
32. Bentzer P, Fjell C, Walley KR, Boyd J, Russell JA. Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Medicine 2016; 42: 1970–9.
33. Willke RJ, Zheng Z, Subedi P, Althin R, Mullins CD. From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Medical Research Methodology 2012; 12: 185.
34. Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. American Journal of Epidemiology 1998; 148: 1117–26.
35. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. American Journal of Respiratory and Critical Care Medicine 2015; 192: 1045–51.
36. Iwashyna TJ, Netzer G, Langa KM, Cigolle C. Spurious inferences about long-term outcomes: the case of severe sepsis and geriatric conditions. American Journal of Respiratory and Critical Care Medicine 2012; 185: 835–41.
37. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. American Journal of Public Health 2005; 95(Suppl 1): S144–50.
38. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 2001; 344: 699–709.
39. Abraham E, Laterre P-F, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine 2005; 353: 1332–41.
40. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. New England Journal of Medicine 2012; 366: 2055–64.
41. Foster JC, Taylor JM. Ruberg SJ Subgroup identification from randomized clinical trial data. Statistics in Medicine 2011; 30: 2867–80.